Mutations and/or Overexpressions of ERG4 and ERG11 Genes in Clinical Azoles-Resistant Isolates of Candida albicans
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: We aimed to investigate whether mutations and/or overexpressions of ERG4 and ERG11 genes were involved in drug resistance to azoles in Candida albicans . Methods: Totally, 34 clinical isolates of C. albicans were included in this study. Antimicrobial susceptibility tests, including 5-fluorocytosine (5-FC), amphotericin B (AMB), fluconazole (FCA), itraconazole (ITR), and voriconazole (VRC), were performed by broth microdilution method. Mutations in the ERG4 and ERG11 genes sequence were detected. The messenger RNA (mRNA) levels of ERG4 and ERG11 were measured by quantitative real-time polymerase chain reaction. The correlation of the expression levels of ERG4 with ERG11 genes in susceptible isolates and resistant isolates was analyzed by Pearson's correlation analysis. Results: Among 34 C. albicans isolates, 52.94%, 70.59%, and 50.00% isolates were resistant to FCA, ITR, and VRC, respectively. Sequencing results revealed that only 2 silent mutations were found in ERG4 gene, while 10 amino acid substitutions, including 6 reported previously and 4 new identified, were frequently found in ERG11 gene. The mRNA levels of ERG4 and ERG11 genes were significantly elevated in resistant compared with susceptible C. albicans isolates. Furthermore, the mRNA level of ERG4 was positively correlated with ERG11 in susceptible but not resistant C. albicans isolates. Conclusions: The resistance to azoles may be associated with the mutations in ERG11 but not ERG4 gene in C. albicans isolates. In addition, overexpressed ERG4 and ERG11 genes are found in resistant C. albicans isolates, and the mRNA levels of ERG4 may be irrelevant to ERG11 in resistant C. albicans isolates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“albicans infections.(2) Currently, antifungal azoles, including fluconazole (FCA), itraconazole (ITR), and voriconazole (VRC) have been considered as the main clinical treatment for C.”
BackgroundEpidemiology and risk factors for invasive candidiasis
Yapar, N. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s40160 · Cited by 610 · cited 1×
“Candida albicans is a common opportunistic fungus inhabiting in skin and/or mucosal surfaces, and it causes some ailments, including invasive infection in skin, mucous membrane or internal organs, and candidemia.(1) Patients with invasive treatment, organ transplantation, and immunodeficiency are increasing due to the…”
BackgroundPerea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470 · cited 1×
“albicans.(8) ERG11 gene, which codes cytochrome P450 lanosterol 14a-demethylase (Erg11p), is a target enzyme of azoles.”
BackgroundResistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461
Franz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339 · cited 1×
“Antifungal azoles can inhibit the growth of fungi through preventing ergosterol synthetic pathway.(6,7) The alterations and/ or overexpressions of ERG genes, targeting enzyme genes in ergosterol synthetic pathways, are considered as the major azoles-resistance mechanism in C.”
BackgroundStress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285 · cited 1×
“albicans infections.(3,4) Unfortunately, the wide use of azoles in clinical practice of C.”
BackgroundUpregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors
Henry, K. W., Nickels, J. T., & Edlind, T. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2693-2700.2000 · Cited by 216
Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans
Xiang, M.-J., Liu, J.-Y., Ni, P.-H., Wang, S., Shi, C., Wei, B., Ni, Y.-X., & Ge, H.-L. (2013) · FEMS Yeast Research · doi:10.1111/1567-1364.12042 · Cited by 197 · cited 2×
“albicans isolates, which was inconsistent with the study of Xiang et al.(30) Thus, the relationship of A114V, K128T, or E266D substitution and resistance to azoles should be further investigated.”
ResultEvolution of Drug Resistance in Candida Albicans
Cowen, L. E., Anderson, J. B., & Kohn, L. M. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160907 · Cited by 151 · cited 1×
“FCA, ITR, and VRC are the most frequently utilized antifungal azole due to good safety, high oral bioavailability, and extensive efficacy against most pathogens.(18,19) It had been reported that azole-resistant C.”
Background
Cited by
Bilal, H., Shafiq, M., Hou, B., Islam, R., Khan, M. N., Khan, R. U., & Zeng, Y. (2022) · Virulence · doi:10.1080/21505594.2022.2123325 · Cited by 91
Ergosterol Biosynthesis and Regulation Impact the Antifungal Resistance and Virulence of Candida spp
Eliaš, D., Tóth Hervay, N., & Gbelská, Y. (2024) · Stresses · doi:10.3390/stresses4040041 · Cited by 63
“On the other hand, CaERG11 gene overexpression is a common mechanism leading to azole resistance in C. albicans clinical isolates [50,127,128].”
Candida tropicalis distribution and drug resistance is correlated with ERG11 and UPC2 expression
Wang, D., An, N., Yang, Y., Yang, X., Fan, Y., & Feng, J. (2021) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-021-00890-2 · Cited by 52
Monroy-Pérez, E., Rodríguez-Bedolla, R. M., Garzón, J., Vaca-Paniagua, F., Arturo-Rojas Jiménez, E., & Paniagua-Contreras, G. L. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104436 · Cited by 25
Expression pattern of drug-resistance genes ERG11 and TAC1 in Candida albicans Clinical isolates
Zare-Bidaki, M., Maleki, A., Ghanbarzadeh, N., & Nikoomanesh, F. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07878-0 · Cited by 15
Metadata
- Authors
- Feng, W., Yang, J., Xi, Z., Qiao, Z., Lv, Y., Wang, Y., Ma, Y., Wang, Y., & Cen, W.
- Venue
- Microbial Drug Resistance
- Publisher
- SAGE Publications
- Published
- 2017-07
- Volume
- 23
- Issue
- 5
- Pages
- 563-570
- ISSN
- 1076-6294 (ISSN-L)
- 1931-8448
- OpenAlex
- W2564016800
- Cited by
- 45
- References
- 9
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.